Bone mineral density in patients with multiple sclerosis: The effects of interferon;Densidad mineral ósea en pacientes con esclerosis múltiple: Efecto del interferón

Revista de Neurologia

Volumn 36, Issue 10, 2003, Pages 901-903

  Pérez Castrillón, José Luis ^a   Cano del Pozo, M ^a   Sanz Izquierdo, S ^a   Velayos Jimenez J ^a   Dib Wobakin, W ^a  

^a HOSPITAL UNIVERSITARIO RÍO HORTEGA   (Spain)

Author keywords

Bone mineral density; Bone remodelling; Corticoids; Interferon; Multiple sclerosis; Osteoporosis

Indexed keywords

CORTICOSTEROID; DEOXYPYRIDINOLINE; INTERFERON; OSTEOCALCIN; PARATHYROID HORMONE; VITAMIN D;

ADULT; ARTICLE; BONE DENSITY; BONE METABOLISM; BONE MINERAL; BONE REMODELING; CALCANEUS; CLINICAL ARTICLE; CONTROLLED STUDY; DENSITOMETRY; DRUG EFFECT; HUMAN; MULTIPLE SCLEROSIS; OSTEOCLAST;

EID: 0038311837     PISSN: 02100010     EISSN: None     Source Type: Journal    
DOI: 10.33588/rn.3610.2002555     Document Type: Article

References (10)

1. Troiano RA, Jotkowiitz A, Cook SD, Bansil S, Zito G. Rate and type of fractures in corticosteroid-treated multiple sclerosis patients. Neurology 1992; 42: 1389-91.
2. Cosman F, Nieves J, Komar L, Ferrer G, Hervert J, Formica C, et al. Fracture history and bone loss in patients with MS. Neurology 1998; 51: 1161-5.
3. Nieves J, Cosman F, Herbert J, Shen V, Lindsay R. High prevalence of vitamin D deficiency and reduced bone mass in multiple sclerosis. Neurology 1994; 44: 1687-92.
4. Poser CM, Paty DW, Scheinberg L, McDonald W, Davis F, Ebers GC, et al. New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 1983; 13: 227-31.
5. Takayanagi H, Kim S, Matsuo K, Suzuki H, Suzuki T, Sato K, et al. RANKL maintains bone homeostasis through c-Fos-dependent induction of interferon-β. Nature 2002; 416: 744-9.
6. Lehmann T, Beyeler C, Lammle B, Hunziker T, Vock P, Olah AJ, et al. Severe osteoporosis due to systemic mast cell disease: successful treatment with interferon alfa-2β. Br J Rheumatol 1996; 35: 898-900.
7. Kauppila M, Koskinen P, Pulkki K, Sonninen P, Remes K, Irjala K, et al. Interferon-alpha treatment decreases serum cross-linked-C-terminal telopeptide of type I collagen in haematological disease. Clin Lab Haematol 2000; 22: 15-20.
8. Solís-Herruzo JA, Castellano G, Fernández I, Muñoz R, Hawkins F. Decreased bone mineral density after therapy with alpha interferon in combination with ribavirin for chronic hepatitis C. J Hepatol 2000; 33: 812-7.
9. Schwid SR, Goodman AD, Puzas JE, McDermott MP, Mattson DH. Sporadic corticosteroid pulses and osteoporosis in multiple sclerosis. Arch Neurol 1996; 53: 753-7.
10. Fornica CA, Cosman F, Nieves J, Herbert J, Lindsay R. Reduced bone mass and fat free mass in women with multiple sclerosis: Effects of ambulatory status and glucocorticoid use. Calcif Tissue Int 1997; 61: 129-33.